PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Analyze analyst forecasts for the company and compare them with competitors.
9.68M
Worse than SAVA's estimated revenue of 50.00M.
-1.93M
Worse than SAVA's estimated ebitda of 0.
-1.38
Worse than SAVA's estimated eps of -0.43.
-41.62M
Worse than SAVA's estimated net income of -18.24M.
-1.93M
Worse than SAVA's estimated ebit of 0.
358.54M
Worse than SAVA's estimated sg&a expense of -66.56B.
Analyze DCF forecasts for the company and compare them with competitors.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-21.77M
Worse than SAVA's ebitda of -6.31M.
100.00%
Equal to SAVA's ebitda margin of 100.00%.
-22.21M
Worse than SAVA's ebit of -6.33M.
100.00%
Equal to SAVA's ebit margin of 100.00%.
447.00K
Worse than SAVA's depreciation of 22.00K.
63.56M
Worse than SAVA's total cash of 93.51M.
100.00%
Equal to SAVA's cash as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to SAVA's receivables as percentage of revenue of 100.00%.
No Data
No DCF data available for this metric in the selected year.
100.00%
Equal to SAVA's inventories as percentage of revenue of 100.00%.
4.34M
Worse than SAVA's accounts payable of 911.00K.
100.00%
Equal to SAVA's payables as percentage of revenue of 100.00%.
-253.00K
Better than SAVA's capital expenditure of 0.00.
100.00%
Equal to SAVA's capex as percentage of revenue of 100.00%.
4.99%
Better than SAVA's weighted average cost of capital (wacc) of 5.34%.
5.02%
Better than SAVA's cost of equity of 5.34%.
4.08%
Better than SAVA's cost of debt of 4.40%.
-0.23
Worse than SAVA's beta of -0.58.
30.07M
Better than SAVA's diluted shares outstanding of 41.93M.
1.57M
Worse than SAVA's total debt of 0.00.
49.31M
Worse than SAVA's total equity of 101.06M.
50.89M
Worse than SAVA's total capital of 101.06M.
3.09%
Worse than SAVA's debt weighting of 0.00%.
96.91%
Worse than SAVA's equity weighting of 100.00%.
-22.04M
Worse than SAVA's ebiat of -5.85M.
-17.50M
Worse than SAVA's unlevered free cash flow of -5.37M.
2.00%
Equal to SAVA's long-term growth rate of 2.00%.
No Data
No DCF data available for this metric in the selected year.
No Data
No DCF data available for this metric in the selected year.
-71.33M
Worse than SAVA's net debt of -121.14M.
71.33M
Worse than SAVA's equity value of 112.01M.
2.37
Worse than SAVA's equity value per share of 2.67.
View analysts' price targets and recommendations, and compare them with competitors.
$11.07
Analysts expect the stock price to increase by 521.91%.
Buy
Positive consensus among analysts.